Neurizon’s lead drug crosses blood-brain barrier, reinforcing ALS treatment potential

Neurizon confirms positive results for prospective ALS treatment - Pharmafile

Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 Sulfone, effectively cross the blood-brain barrier (BBB) and reach concentrations in the brain sufficient to reverse toxic TDP-43 protein aggregation – a key driver of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). In a rodent pharmacokinetic study, both compounds […] The post Neurizon confirms positive res…

Neurizon’s lead drug crosses blood-brain barrier, reinforcing ALS treatment potential

PK study shows strong brain penetration of NUZ-001 and major active metabolite NUZ-001 Sulfone Both compounds significantly prevented TDP-43 aggregation in a patient-derived ALS neuron model at all tested concentrations Brain concentrations reached matched those needed to reverse TDP-43 aggregation   Special Report: Clinical-stage biotech Neurizon Therapeutics has reported encouraging new rodent preclinical pharmacokinetic (PK) data for its lead…